“Heart disease in humans is a huge health issue, but in dogs it’s an even bigger problem,” said lead investigator Andrew McDonald, a research associate in stethoscope acoustics with the ...
The Dutch biotech Synaffix has long been one of the top partners for biopharma companies working in antibody-drug conjugates. Now the company is spinning out … ...
Kivu is joining in. Chief Operating Officer Mohit Trikha said that ADC tolerability has limited how large of a dose developers can safely use, or cause people to stop treatment. Unstable linker ...
“The preliminary results from the ongoing Phase 1 trial of ZL-1310 suggest that this next-generation ADC therapy has the potential to deliver anti-tumor responses in the majority of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback